Abstract
Rationale
Patients suffering from Alzheimer’s disease (AD) experience a marked reduction in cortical nicotinic acetylcholine receptors (nAChRs). In particular, selective loss of the α4β2 nAChR subtype was observed in postmortem AD brain tissue. The α4 and α7 nAChR subunits were suggested to play an important role in cognitive function. Positron emission tomography (PET) has so far been used to visualize neuronal nAChRs in vivo by 11C-nicotine binding.
Objectives
To investigate the relationship between measures of cognitive function and in vivo 11C-nicotine binding in mild AD brain as assessed by PET.
Materials and methods
Twenty-seven patients with mild AD were recruited in this study. A dual tracer model with administration of 15O-water for regional cerebral blood flow and (S)(−)11C-nicotine was used to assess nicotine binding sites in the brain by PET. Cognitive function was assessed using neuropsychological tests of global cognition, episodic memory, attention, and visuospatial ability.
Results
Mean cortical 11C-nicotine binding significantly correlated with the results of attention tests [Digit Symbol test (r=−0.44 and p=0.02) and Trail Making Test A (TMT-A) (r=0.42 and p=0.03)]. No significant correlation was observed between 11C-nicotine binding and the results of tests of episodic memory or visuospatial ability. Regional analysis showed that 11C-nicotine binding in the frontal and parietal cortex, which are the main areas for attention, correlated significantly with the Digit Symbol test and TMT-A results.
Conclusion
Cortical nicotinic receptors in vivo in mild AD patients are robustly associated with the cognitive function of attention.
Similar content being viewed by others
References
Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies. Am J Psychiatry 159:738–745
Alhainen K, Helkala EL, Riekkinen P (1993) Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer patients. Dementia 4:54–58
Almkvist O, Jelic V, Amberla K, Hellstrom-Lindahl E, Meurling L, Nordberg A (2001) Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord 12:22–32
Anderson J (1995) A rapid and accurate method to realign PET-scans utilizing image edge information. J Nucl Med 36:657–669
Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R (1992) Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer’s and Parkinson’s diseases. J Neurochem 58:529–541
Backman L, Forsell Y (1994) Episodic memory functioning in a community-based sample of old adults with major depression: utilization of cognitive support. J Abnorm Psychol 103:361–370
Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG, Constantine G, Mathis CA, Moore RY, DeKosky ST (2005) Cognitive correlates of alterations in acetylcholinesterase in Alzheimer’s disease. Neurosci Lett 380:127–132
Cabeza R, Nyberg L (2000) Imaging cognition II: an empirical review of 275 PET and fMRI studies. J Cogn Neurosci 12:1–47
Cahn-Weiner DA, Sullivan EV, Shear PK, Fama R, Lim KO, Yesavage JA, Tinklenberg JR, Pfefferbaum A (1999) Brain structural and cognitive correlates of clock drawing performance in Alzheimer’s disease. J Int Neuropsychol Soc 5:502–509
Calhoun ME, Mao Y, Roberts JA, Rapp PR (2004) Reduction in hippocampal cholinergic innervation is unrelated to recognition memory impairment in aged rhesus monkeys. J Comp Neurol 475:238–246
Chefer SI, London ED, Koren AO, Pavlova OA, Kurian V, Kimes AS, Horti AG, Mukhin AG (2003) Graphical analysis of 2-[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. Synapse 48:25–34
Coyle JT, Price DL, DeLong MR (1983) Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219:1184–1190
Ding YS, Fowler JS, Logan J, Wang GJ, Telang F, Garza V, Biegon A, Pareto D, Rooney W, Shea C, Alexoff D, Volkow ND, Vocci F (2004) 6-[18F]Fluoro-A-85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse 53:184–189
Duchek JM, Hunt L, Ball K, Buckles V, Morris JC (1997) The role of selective attention in driving and dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 1(Suppl 11):48–56
Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ (1992) A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41:31–37
Foldi NS, Lobosco JJ, Schaefer LA (2002) The effect of attentional dysfunction in Alzheimer’s disease: theoretical and practical implications. Semin Speech Lang 23:139–150
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro G (1983) Alzheimer’s disease: focal cortical changes shown by positron emission tomography. Neurology 33:961–965
Gallezot JD, Bottlaender M, Gregoire MC, Roumenov D, Deverre JR, Coulon C, Ottaviani M, Dolle F, Syrota A, Valette H (2005) In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. J Nucl Med 46:240–247
Guan ZZ, Zhang X, Ravid R, Nordberg A (2000) Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer’s disease. J Neurochem 74:237–243
Guillozet AL, Weintraub S, Mash DC, Mesulam MM (2003) Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 60:729–736
Gundisch D, Koren AO, Horti AG, Pavlova OA, Kimes AS, Mukhin AG, London ED (2005) In vitro characterization of 6-[18F]fluoro-A-85380, a high-affinity ligand for alpha4beta2* nicotinic acetylcholine receptors. Synapse 55:89–97
Haxby JV, Duara R, Grady CL, Cutler NR, Rapoport SI (1985) Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer’s disease. J Cereb Blood Flow Metab 5:193–200
Herholz K, Adams R, Kessler J, Szelies B, Grond M, Heiss W (1990) Criteria for the diagnosis of Alzheimer’s disease with positron emission tomography. Dementia 1:156–164
Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, Halber M, Jelic V, Almkvist O, Collette F, Alberoni M, Kennedy A, Hasselbalch S, Fazio F, Heiss WD (1999) Impairment of neocortical metabolism predicts progression in Alzheimer’s disease. Dement Geriatr Cogn Disord 10:494–504
Herscovitch P, Markham J, Raichle ME (1983) Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis. J Nucl Med 24:782–789
Ikonomovic MD, Mufson EJ, Wuu J, Cochran EJ, Bennett DA, DeKosky ST (2003) Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer’s neuropathology. J Alzheimers Dis 5:39–48
Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992) Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease. Psychopharmacology (Berl) 108:485–494
Kadir A, Almkvist O, Wall A, Darreh-Shori T, Grut M, Strandberg B, Ringheim A, Erikson B, Blomquist G, Långström B, Nordberg A (2006a) PET imaging of acetylcholinesterase activity and nicotinebinding in galantamine treated AD patients. In preparation
Kadir A, Darreh-Shori T, Almkvist O, Wall A, Långström B, Nordberg A (2006b) Changes in the brain 11C-nicotine bindingsites in mild AD patients following rivastigmine treatment assessed by PET. In preparation
Lawrence AD, Sahakian BJ (1995) Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord 2(Suppl 9):43–49
Lezak M (1995) Neuropsychological assessment, 3rd edn. Oxford University Press, London, UK
Lundqvist H, Nordberg A, Hartvig P, Langstrom B (1998) (S)-(−)-[11C]nicotine binding assessed by PET: a dual tracer model evaluated in the rhesus monkey brain. Alzheimer Dis Assoc Disord 12:238–246
Luria A (1966) Higher cortical functions in man. Basic Books, New York
Maziere M, Delforge J (1995) PET imaging [11C]nicotine: historical aspects. In: Domino E (ed) Brain imaging of nicotine and tobacco smoking. NPP Books, Ann Arbor, pp 13–28
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944
Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, O’Connor SM, Carter MF, Amezcua H, Cummings JL (2005) Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol 62:721–728
Mogg AJ, Jones FA, Pullar IA, Sharples CG, Wonnacott S (2004) Functional responses and subunit composition of presynaptic nicotinic receptor subtypes explored using the novel agonist 5-iodo-A-85380. Neuropharmacology 47:848–859
Nagahama Y, Okina T, Suzuki N, Nabatame H, Matsuda M (2005) Neural correlates of impaired performance on the clock drawing test in Alzheimer’s disease. Dement Geriatr Cogn Disord 19:390–396
Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL (1988) Intravenous nicotine in Alzheimer’s disease: a pilot study. Psychopharmacology (Berl) 95:171–175
Nobili F, Brugnolo A, Calvini P, Copello F, De Leo C, Girtler N, Morbelli S, Piccardo A, Vitali P, Rodriguez G (2005) Resting SPECT–neuropsychology correlation in very mild Alzheimer’s disease. Clin Neurophysiol 116:364–375
Nordberg A (1999) PET studies and cholinergic therapy in Alzheimer’s disease. Rev Neurol (Paris) 4(Suppl 155):S53–S63
Nordberg A (2001) Nicotinic receptor abnormalities of Alzheimer’s disease: therapeutic implications. Biol Psychiatry 49:200–210
Nordberg A (2006) Visualization of nicotinic and muscarinic receptors in brain by positron emission tomography. In: Ezio G, Pepeu G (eds) The brain cholinergic system. Martin Dunitz, London
Nordberg A, Winblad B (1986) Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 72:115–119
Nordberg A, Hartvig P, Lilja A, Viitanen M, Amberla K, Lundqvist H, Andersson Y, Ulin J, Winblad B, Langstrom B (1990) Decreased uptake and binding of 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neural Transm Park Dis Dement Sect 2:215–224
Nordberg A, Alafuzoff I, Winblad B (1992) Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res 31:103–111
Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B (1995) Kinetic analysis of regional (S)(−)11C-nicotine binding in normal and Alzheimer brains—in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 9:21–27
Nordberg A, Lundqvist H, Hartvig P, Andersson J, Johansson M, Hellstrom-Lindahi E, Langstrom B (1997) Imaging of nicotinic and muscarinic receptors in Alzheimer’s disease: effect of tacrine treatment. Dement Geriatr Cogn Disord 8:78–84
Nordberg A, Amberla K, Shigeta M, Lundqvist H, Viitanen M, Hellstrom-Lindahl E, Johansson M, Andersson J, Hartvig P, Lilja A, Langstrom B, Winblad B (1998) Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis Assoc Disord 12:228–237
Ober BA, Jagust WJ, Koss E, Delis DC, Friedland RP (1991) Visuoconstructive performance and regional cerebral glucose metabolism in Alzheimer’s disease. J Clin Exp Neuropsychol 13:752–772
Pabreza LA, Dhawan S, Kellar KJ (1991) [3H]Cytisine binding to nicotinic cholinergic receptors in brain. Mol Pharmacol 39:9–12
Paterson D, Nordberg A (2000) Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61:75–111
Perry RJ, Hodges JR (2000) Fate of patients with questionable (very mild) Alzheimer’s disease: longitudinal profiles of individual subjects’ decline. Dement Geriatr Cogn Disord 11:342–349
Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nasland J, Davis K, Gotti C, Clementi F, Tzartos S, Cohen O, Soreq H, Jaros E, Perry R, Ballard C, McKeith I, Court J (2000) Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 393:215–222
Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA (1999) Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer’s disease. Psychopharmacology (Berl) 142:334–342
Raichle ME, Martin WR, Herscovitch P, Mintun MA, Markham J (1983) Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. J Nucl Med 24:790–798
Robbins TW, McAlonan G, Muir JL, Everitt BJ (1997) Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer’s disease. Behav Brain Res 83:15–23
Robertson LC, Lamb MR, Knight RT (1988) Effects of lesions of temporal-parietal junction on perceptual and attentional processing in humans. J Neurosci 8:3757–3769
Rusted JM, Graupner L, Tennant A, Warburton DM (1998) Effortful processing is a requirement for nicotine-induced improvements in memory. Psychopharmacology (Berl) 138:362–368
Rusted JM, Newhouse PA, Levin ED (2000) Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer’s disease and Parkinson’s disease. Behav Brain Res 113:121–129
Sahakian BJ, Jones GM (1991) The effects of nicotine on attention, information processing, and working memory in patients with dementia of the Alzheimer type. In: Adlkofer F, Thruau K (eds) Effects of nicotine on biological system. Birkhauser Verlag, Basel
Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, Crockford HA, Crooks M, Hill K, Levy R (1993) Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer’s disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology (Berl) 110:395–401
Sihver W, Fasth KJ, Horti AG, Koren AO, Bergstrom M, Lu L, Hagberg G, Lundqvist H, Dannals RF, London ED, Nordberg A, Langstrom B (1999) Synthesis and characterization of binding of 5-[76Br]bromo-3-[[2(S)-azetidinyl]methoxy]pyridine, a novel nicotinic acetylcholine receptor ligand, in rat brain. J Neurochem 73:1264–1272
Snaedal J, Johannesson T, Jonsson JE, Gylfadottir G (1996) The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer’s disease. Dementia 7:47–52
Teipel SJ, Willoch F, Ishii K, Burger K, Drzezga A, Engel R, Bartenstein P, Moller HJ, Schwaiger M, Hampel H (2005) Resting state glucose utilization and the CERAD cognitive battery in patients with Alzheimer’s disease. Neurobiol Aging 27(5):681–690
Vellas B, Cunha L, Gertz HJ, De Deyn PP, Wesnes K, Hammond G, Schwalen S (2005) Early onset effects of galantamine treatment on attention in patients with Alzheimer’s disease. Curr Med Res Opin 21:1423–1429
Vitaliano PP, Breen AR, Albert MS, Russo J, Prinz PN (1984) Memory, attention, and functional status in community-residing Alzheimer type dementia patients and optimally healthy aged individuals. J Gerontol 39:58–64
Voytko ML, Olton DS, Richardson RT, Gorman LK, Tobin JR, Price DL (1994) Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 14:167–186
Walsh DM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 44:181–193
Warpman U, Nordberg A (1995) Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport 6:2419–2423
Watson CCND, Casey ME et al (1997) Evaluation of simulation based scatter correction for 3D PET cardiac imaging. IEEE Trans Nucl Sci 21:136–144
Wechsler D (1981) Wechsler Adult Intelligence Scale—revised manual. Psychological Corporation, New York
Wevers A, Monteggia L, Nowacki S, Bloch W, Schutz U, Lindstrom J, Pereira EF, Eisenberg H, Giacobini E, de Vos RA, Steur EN, Maelicke A, Albuquerque EX, Schroder H (1999) Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer’s disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 11:2551–2565
White HK, Levin ED (1999) Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer’s disease. Psychopharmacology (Berl) 143:158–165
White HK, Levin ED (2004) Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology (Berl) 171:465–471
Wilson AL, Langley LK, Monley J, Bauer T, Rottunda S, McFalls E, Kovera C, McCarten JR (1995) Nicotine patches in Alzheimer’s disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 51:509–514
Yu WF, Guan ZZ, Bogdanovic N, Nordberg A (2005) High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer’s disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol 192:215–225
Acknowledgements
This research was supported by the Swedish Research Council (project no. 05817), Stiftelsen for Gamla Tjänarinnor, Stohne’s Foundation, and Swedish Brain Power.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kadir, A., Almkvist, O., Wall, A. et al. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease. Psychopharmacology 188, 509–520 (2006). https://doi.org/10.1007/s00213-006-0447-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-006-0447-7